Causaly Raises $60M in Series B Funding

The latest round comes after Causaly tripled revenue! Causaly's hybrid method merges a knowledge graph and generative AI, facilitating deep, impartial scientific research. This technology is widely utilized by research teams for tasks like target identification and biomarker discovery.

We are excited to accelerate our platform investments and partner with our customers in ingesting proprietary data to truly transform the way that research is done today" - Artur Saudabayev, Co-founder and CTO of Causaly.

Funding led by: ICONIQ Growth

Participation from: Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club.

Strategic individuals: Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog)

Customers Include: Gilead, Novo Nordisk, Regeneron, the Food and Drug Administration and the National Institute of Environmental Health Sciences.

Total Funding Amount: $93M

Funds Use: To extend its product lead and expand commercial relationships.

About: Causaly  develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine.